Q3 2024 Earnings Call Transcript November 4, 2024 Verona Pharma plc beats earnings expectations. Reported EPS is $-0.08819, ...
15h
Verona Pharma PLC (VRNA) reports significant sales growth for Ohtuvayre, but faces increased expenses and competition in the COPD market.
Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Verona Pharma (VRNA – Research Report), boosting the price target to ...
The first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor – now given the somewhat tongue-twisting brand name of Ohtuvayre – is the first inhaled product with a novel mechanism of action ...
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company ...
Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3Through October more than 2,200 unique ...
Ritedose is the development partner and manufacturer of Ohtuvayre (ensifentrine)*, the first inhaled product with a novel mechanism of action in more than 20 years for the maintenance treatment of ...
In June, the Food and Drug Administration (FDA) approved Ohtuvayre (ensifentrine), the company's lead candidate. Verona’s stock has surged 36.8% YTD, outperforming the broader market's gain.
Hosted on MSN3mon
Verona (VRNA) Stock Surges 36% in the Past Month: Here's WhyShares of Verona Pharma VRNA have soared 36.3% since the past month, all thanks to the FDA’s approval of its lead pipeline drug in chronic obstructive pulmonary disease (COPD) indication.
Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 in a broad COPD population LONDON and RALEIGH, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback